— Obalon Therapeutics (NASDAQ: OBLN) reported a net loss of $0.61 per share for the third quarter of 2019, vs. $2.14 per share loss expected.
— Third-quarter net loss was $3.7 million, compared to a loss of $6.7 million a year earlier
— Revenue decreased to $0.3 million from $3.0 million in the third quarter of 2018, vs. $1.2 million loss expected
— Cost of revenue was $0.4 million, down from $1.4 million in the same period of last year
— Research and development expense declined sharply to $1.2 million from $2.4 million last year
— Opened the first company-owned retail treatment center, the Obalon Center for Weight Loss
— Raised $16.6 million in gross proceeds from an equity offering
— Promoted William Plovanic to President and CEO; promoted Nooshin Hussainy to CFO
Most Popular
V Earnings: Key quarterly highlights from Visa’s Q1 2023 financial results
Visa Inc. (NYSE: V) reported first quarter 2023 earnings results today. Net revenues grew 12% year-over-year to $7.9 billion. GAAP net income rose 6% to $4.2 billion while EPS grew
Earnings: Highlights of Intel’s (INTC) Q4 2022 financial results
Intel Corporation (NASDAQ: INTC) Thursday reported a decline in adjusted earnings and revenues for the fourth quarter. The semiconductor giant also provided guidance for the first quarter of 2023. Fourth-quarter
McCormick (MKC) expects to drive sales growth in 2023 through pricing actions and cost savings
Shares of McCormick & Company Inc. (NYSE: MKC) were down over 5% on Thursday after the company missed expectations on its fourth quarter 2022 results and provided a lower-than-expected earnings